Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 2,602 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 2,602 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $45.02, for a total transaction of $117,142.04. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $564,820.92. This represents a 17.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kiniksa Pharmaceuticals International Trading Down 3.2%

KNSA stock traded down $1.44 during trading on Wednesday, hitting $43.52. The company had a trading volume of 523,927 shares, compared to its average volume of 698,512. The company has a market cap of $3.30 billion, a P/E ratio of 96.71 and a beta of 0.06. The company has a fifty day moving average price of $41.78 and a two-hundred day moving average price of $38.06. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $18.12 and a fifty-two week high of $45.50.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same period in the previous year, the company posted ($0.18) EPS. The firm’s revenue for the quarter was up 61.2% compared to the same quarter last year. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amundi bought a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares during the last quarter. Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Kiniksa Pharmaceuticals International by 13.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company’s stock valued at $430,000 after acquiring an additional 1,846 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $233,000. 53.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KNSA. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.